How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent upward trend in key financial metrics over the past four years.

Breakdown:
Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income has similarly risen, reaching 1,200.09 Cr in Mar'25, up from 712.93 Cr in Mar'22. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) has shown significant improvement, climbing from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, while profit before tax rose from 241.16 Cr to 495.87 Cr in the same period. Consequently, profit after tax increased from 178.57 Cr in Mar'22 to 372.96 Cr in Mar'25, leading to an earnings per share (EPS) growth from 16.72 to 35.53. The company's total assets have expanded from 1,312.79 Cr in Mar'22 to 2,034.25 Cr in Mar'25, while total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, with a notable reduction in debt from 60.59 Cr to 0.38 Cr. Cash flow from operating activities has remained positive, although there was a net cash outflow of 14.00 Cr in Mar'25, down from an inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech has demonstrated robust growth in sales, profits, and asset base, while effectively managing its liabilities.